Tekla Operating Cycle from 2010 to 2026

HQH Stock  USD 19.89  0.30  1.53%   
Tekla Healthcare's Operating Cycle is decreasing with stable movements from year to year. Operating Cycle is predicted to flatten to 18.35. For the period between 2010 and 2026, Tekla Healthcare, Operating Cycle quarterly trend regression had mean deviation of  218.58 and range of 1.2 K. View All Fundamentals
 
Operating Cycle  
First Reported
2010-12-31
Previous Quarter
19.32
Current Value
18.35
Quarterly Volatility
330.46569381
 
Credit Downgrade
 
Yuan Drop
 
Covid
 
Interest Hikes
Check Tekla Healthcare financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Tekla Healthcare's main balance sheet or income statement drivers, such as Depreciation And Amortization of 188.3 K, Interest Expense of 0.0 or Selling General Administrative of 1.3 M, as well as many indicators such as Price To Sales Ratio of 174, Dividend Yield of 0.0762 or PTB Ratio of 1.0. Tekla financial statements analysis is a perfect complement when working with Tekla Healthcare Valuation or Volatility modules.
  
Build AI portfolio with Tekla Stock
Check out the analysis of Tekla Healthcare Correlation against competitors.
The Operating Cycle trend for Tekla Healthcare Investors offers valuable insights into the company's financial trajectory and strategic direction. By examining multi-year patterns, investors can identify whether Tekla Healthcare is strengthening or weakening its position, and how this metric correlates with broader market conditions and industry benchmarks.

Latest Tekla Healthcare's Operating Cycle Growth Pattern

Below is the plot of the Operating Cycle of Tekla Healthcare Investors over the last few years. It is Tekla Healthcare's Operating Cycle historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Tekla Healthcare's overall financial position and show how it may be relating to other accounts over time.
Operating Cycle10 Years Trend
Pretty Stable
   Operating Cycle   
       Timeline  

Tekla Operating Cycle Regression Statistics

Arithmetic Mean204.19
Geometric Mean58.26
Coefficient Of Variation161.84
Mean Deviation218.58
Median24.70
Standard Deviation330.47
Sample Variance109,208
Range1.2K
R-Value(0.13)
Mean Square Error114,370
R-Squared0.02
Significance0.61
Slope(8.83)
Total Sum of Squares1.7M

Tekla Operating Cycle History

2026 18.35
2025 19.32
2024 16.8
2023 243.08
2022 126.56
2021 227.88
2020 176.59

About Tekla Healthcare Financial Statements

Investors use fundamental indicators, such as Tekla Healthcare's Operating Cycle, to determine how well the company is positioned to perform in the future. Although Tekla Healthcare's investors may analyze each financial statement separately, they are all interrelated. Understanding these patterns can help investors make the right trading decisions.
Last ReportedProjected for Next Year
Operating Cycle 19.32  18.35 

Currently Active Assets on Macroaxis

When determining whether Tekla Healthcare Inv offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Tekla Healthcare's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Tekla Healthcare Investors Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Tekla Healthcare Investors Stock:
Check out the analysis of Tekla Healthcare Correlation against competitors.
You can also try the Portfolio Suggestion module to get suggestions outside of your existing asset allocation including your own model portfolios.
Is there potential for Asset Management & Custody Banks market expansion? Will Tekla introduce new products? Factors like these will boost the valuation of Tekla Healthcare. Market participants price Tekla higher when confident in its future expansion prospects. Understanding fair value requires weighing current performance against future potential. All the valuation information about Tekla Healthcare listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
0.911
Dividend Share
2.24
Earnings Share
1.61
Revenue Per Share
0.136
Quarterly Revenue Growth
(0.49)
Tekla Healthcare Inv's market price often diverges from its book value, the accounting figure shown on Tekla's balance sheet. Smart investors calculate Tekla Healthcare's intrinsic value - its true economic worth - which may differ significantly from both market price and book value. Analysts utilize numerous techniques to assess fundamental value, seeking to purchase shares when trading prices fall beneath estimated intrinsic worth. Since Tekla Healthcare's trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
Please note, there is a significant difference between Tekla Healthcare's value and its price as these two are different measures arrived at by different means. Investors typically determine if Tekla Healthcare is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Tekla Healthcare's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.